BGPT: Paper Review: Roles of protein ubiquitination in inflammatory bowel disease

Fuel Your Discoveries

Quick Explanation Copied

Paper: Roles of protein ubiquitination in inflammatory bowel disease (IBD)

A narrative review that organizes many IBD-linked E3 ligases and deubiquitinases into two dominant signaling themes—NF-κB and NOD2→RIPK2—and highlights ubiquitin “linkage/substrate specificity” as a mechanistic axis for intestinal inflammation and epithelial homeostasis.

Primary basis: the review manuscript itself

Long Explanation

Long visual paper analysis

Date of paper (as provided): Nov 2020

Study type: Narrative review (no new primary dataset generation).

1) Mechanistic map (from review)

The review organizes ubiquitin biology in IBD around two recurring signaling “spines”:

NF-κB regulation (examples: RNF183→IκBα degradation; RNF20/RNF40→H2Bub1→NF-κB transcriptional tuning; A20→RIP1 editing; FBXW7/A20-axis themes).
NOD2→RIPK2 (examples: Pellino3 and XIAP-linked RIP2 ubiquitination; MYSM1 DUB trimming polyubiquitin chains on RIPK2 to prevent excessive inflammation; review also notes RIPK2’s kinase function).

2) Visual summary: ubiquitin modifiers covered

From the review text, the following modifier families are explicitly highlighted (E3 ligases and DUBs, plus a few “other” modifiers).

Note: the figure encodes inclusion (count=1 per named modifier), not effect size or prevalence; it is a structural read of the review’s emphasis rather than quantitative biology.

3) Network view: modifier → pathway (qualitative)

The review repeatedly links specific modifiers to particular signaling endpoints. Below is a qualitative bipartite mapping extracted from the paper narrative.

Epistemic humility: a “1” here means the review text links the modifier to that endpoint; it does not prove causal universality across all cell types, IBD subtypes, or experimental conditions.

4) How to critically read the review (skeptical checklist)

Knowns (as the review presents them)

Ubiquitin signaling is positioned as an epigenetic/POST-TRANSLATIONAL regulatory layer in IBD, with repeated emphasis on NF-κB and NOD2 pathways.
The review summarizes multiple named E3 ligases and DUBs with substrate-specific mechanistic claims (e.g., RNF183→IκBα ubiquitination/degradation; A20→editing ubiquitin chains on RIP1 and Wnt-related effects; Pellino3→RIP2 ubiquitination; TRIM62→CARD9 ubiquitination; Itch→RORγt/IL-17 axis; CYLD→TRAF ubiquitination restraint; MYSM1→RIPK2 chain removal).

Uncertainties / what’s not established by the review alone

Selection bias from narrative scope: a narrative review can overrepresent “popular” ubiquitin nodes while omitting others, and it does not guarantee balanced coverage or systematic inclusion criteria.
Context dependence: many cited mechanisms are derived from different experimental systems (human tissue, cell lines, and multiple mouse colitis models). The review does not supply unified, head-to-head evidence showing which ubiquitin chain/substrate effects dominate across IBD subtypes and anatomical regions.
Translation gap: while the review motivates therapeutic targeting, it cannot establish safety/efficacy for any specific intervention because it does not present new clinical trials or translational pipelines.

5) Review’s conceptual “division of labor” (E3 vs DUB)

The review implicitly frames E3 ligases as drivers of pro-activation or attenuation via adding specific ubiquitin chains, and DUBs as brakes that remove/edit those chains to restrain inflammation—particularly within NF-κB-related axes and NOD2/RIPK2 regulation.

Again, this is only an inclusion-frequency proxy, not a measure of effect magnitude or mechanistic certainty.

6) What would disprove the review’s core mechanistic framing?

Given the review’s central thesis (ubiquitin modifiers regulating IBD inflammation via NF-κB and NOD2/RIPK2 axes), falsification would require showing that perturbing these modifiers does not measurably alter the corresponding pathway outputs and disease phenotypes in relevant models.

Pathway output null results: if chain-specific ubiquitination/deubiquitination states on the proposed substrates (e.g., IκBα, RIP1, RIP2/RIPK2, CARD9, RORγt) are disrupted but NF-κB or NOD2→inflammation readouts remain unchanged, the mechanistic linkage is weakened.
Phenotype dissociation: if inflammatory outcomes in colitis models do not shift as predicted when key ligases/DUBs are perturbed (and if genetic effects are compensated by redundant pathway nodes), then the review’s implied causal centrality may be overstated.
Human-specific mismatch: if human tissue data show inconsistent directionality (e.g., no concordance in expression/localization of modifiers or no association with chain/substrate activity), then translational priority would drop.

7) Links for deeper author-focused reading

Click to open BGPT’s dedicated author review pages.

Feedback:

Updated: March 24, 2026